Cargando…

Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018)

INTRODUCTION: Data on utilization, major complications, and in‐hospital mortality of catheter ablation (CA) for sarcoidosis‐related ventricular tachycardia (VT) are limited. We sought to determine the outcomes of sarcoidosis‐related VT, and incidence and predictors of complications associated with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Jian Liang, Jin, Chengyue, Lee, Justin Z., Gaughan, John, Iwai, Sei, Russo, Andrea M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098605/
https://www.ncbi.nlm.nih.gov/pubmed/36335632
http://dx.doi.org/10.1111/jce.15708
_version_ 1785024850074533888
author Tan, Jian Liang
Jin, Chengyue
Lee, Justin Z.
Gaughan, John
Iwai, Sei
Russo, Andrea M.
author_facet Tan, Jian Liang
Jin, Chengyue
Lee, Justin Z.
Gaughan, John
Iwai, Sei
Russo, Andrea M.
author_sort Tan, Jian Liang
collection PubMed
description INTRODUCTION: Data on utilization, major complications, and in‐hospital mortality of catheter ablation (CA) for sarcoidosis‐related ventricular tachycardia (VT) are limited. We sought to determine the outcomes of sarcoidosis‐related VT, and incidence and predictors of complications associated with the CA procedure. METHODS: We queried the 2002–2018 National Inpatient Sample database to identify patients aged ≥18 years with sarcoidosis admitted with VT. A 1:3 propensity score‐matched (PSM) analysis was used to compare patient outcomes between CA and medically managed groups. Multivariable regression was performed to determine independent predictors of in‐hospital mortality and procedural complications associated with the CA procedure. RESULTS: Of 3220 sarcoidosis patients with VT, 132 (4.1%) underwent CA. Patients who underwent CA were younger, male predominant, more likely Caucasian, had differences in baseline comorbidities including more likely to have heart failure, less likely to have prior myocardial infarction, COPD, or severe renal disease, had a higher mean household income, and more likely admitted to a larger/urban teaching hospital. After PSM, we examined 106 CA cases and 318 medically managed cases. There was a trend toward a lower in‐hospital mortality rate in the CA group when compared to the medically managed group (1.9% vs. 6.6%, p = 0.08). The most common complications were pericardial drainage (5.3%), postoperative hemorrhage (3.8%), accidental puncture periprocedure (3.0%), and cardiac tamponade (2.3%). Independent predictors of in‐hospital mortality and procedural complications among the CA group included congestive heart failure (odds ratio [OR], 13.2; 95% confidence interval [CI], 1.7–104.2) and mild to moderate renal disease (OR, 3.9; 95% CI, 1.1–13.3). CONCLUSIONS: Compared to patients with sarcoidosis‐related VT who received medical therapy alone, those who underwent CA have a trend for a lower mortality rate despite procedure‐related complications occurring as high as 9.1%. Additional studies are recommended to better evaluate the benefits and risks of VT ablation in this group.
format Online
Article
Text
id pubmed-10098605
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100986052023-04-14 Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018) Tan, Jian Liang Jin, Chengyue Lee, Justin Z. Gaughan, John Iwai, Sei Russo, Andrea M. J Cardiovasc Electrophysiol Original Articles INTRODUCTION: Data on utilization, major complications, and in‐hospital mortality of catheter ablation (CA) for sarcoidosis‐related ventricular tachycardia (VT) are limited. We sought to determine the outcomes of sarcoidosis‐related VT, and incidence and predictors of complications associated with the CA procedure. METHODS: We queried the 2002–2018 National Inpatient Sample database to identify patients aged ≥18 years with sarcoidosis admitted with VT. A 1:3 propensity score‐matched (PSM) analysis was used to compare patient outcomes between CA and medically managed groups. Multivariable regression was performed to determine independent predictors of in‐hospital mortality and procedural complications associated with the CA procedure. RESULTS: Of 3220 sarcoidosis patients with VT, 132 (4.1%) underwent CA. Patients who underwent CA were younger, male predominant, more likely Caucasian, had differences in baseline comorbidities including more likely to have heart failure, less likely to have prior myocardial infarction, COPD, or severe renal disease, had a higher mean household income, and more likely admitted to a larger/urban teaching hospital. After PSM, we examined 106 CA cases and 318 medically managed cases. There was a trend toward a lower in‐hospital mortality rate in the CA group when compared to the medically managed group (1.9% vs. 6.6%, p = 0.08). The most common complications were pericardial drainage (5.3%), postoperative hemorrhage (3.8%), accidental puncture periprocedure (3.0%), and cardiac tamponade (2.3%). Independent predictors of in‐hospital mortality and procedural complications among the CA group included congestive heart failure (odds ratio [OR], 13.2; 95% confidence interval [CI], 1.7–104.2) and mild to moderate renal disease (OR, 3.9; 95% CI, 1.1–13.3). CONCLUSIONS: Compared to patients with sarcoidosis‐related VT who received medical therapy alone, those who underwent CA have a trend for a lower mortality rate despite procedure‐related complications occurring as high as 9.1%. Additional studies are recommended to better evaluate the benefits and risks of VT ablation in this group. John Wiley and Sons Inc. 2022-11-24 2022-12 /pmc/articles/PMC10098605/ /pubmed/36335632 http://dx.doi.org/10.1111/jce.15708 Text en © 2022 The Authors. Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Tan, Jian Liang
Jin, Chengyue
Lee, Justin Z.
Gaughan, John
Iwai, Sei
Russo, Andrea M.
Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018)
title Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018)
title_full Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018)
title_fullStr Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018)
title_full_unstemmed Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018)
title_short Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018)
title_sort outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: insights from the national inpatient sample database (2002–2018)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098605/
https://www.ncbi.nlm.nih.gov/pubmed/36335632
http://dx.doi.org/10.1111/jce.15708
work_keys_str_mv AT tanjianliang outcomesofcatheterablationforventriculartachycardiainpatientswithsarcoidosisinsightsfromthenationalinpatientsampledatabase20022018
AT jinchengyue outcomesofcatheterablationforventriculartachycardiainpatientswithsarcoidosisinsightsfromthenationalinpatientsampledatabase20022018
AT leejustinz outcomesofcatheterablationforventriculartachycardiainpatientswithsarcoidosisinsightsfromthenationalinpatientsampledatabase20022018
AT gaughanjohn outcomesofcatheterablationforventriculartachycardiainpatientswithsarcoidosisinsightsfromthenationalinpatientsampledatabase20022018
AT iwaisei outcomesofcatheterablationforventriculartachycardiainpatientswithsarcoidosisinsightsfromthenationalinpatientsampledatabase20022018
AT russoandream outcomesofcatheterablationforventriculartachycardiainpatientswithsarcoidosisinsightsfromthenationalinpatientsampledatabase20022018